Compare Home Depot Inc (HD) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Home Depot Inc vs Recursion Pharmaceuticals Inc — how do they compare? Home Depot Inc trades at $332.79 (market cap $332.08B), while Recursion Pharmaceuticals Inc trades at $3.05 (market cap $1.53B). The key difference: Home Depot Inc is far larger — about 217× Recursion Pharmaceuticals Inc's market cap, and Home Depot Inc pays a 2.8% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| HD | RXRX | |
|---|---|---|
Market Cap | $332.08B | $1.53B |
Sector | Consumer Cyclical | Health |
52-Week High | $423.42 | $6.79 |
52-Week Low | $297.51 | $2.84 |
Enterprise Value | $393.64B | $946.50M |
Dividend Yield | 2.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $330.95, down 2.34% on the day, approaching its 52-week low amid broader market weakness in home improvement stocks. The company reported mixed quarterly earnings with a Q3 2025 miss but subsequent beats, while maintaining solid profitability with 8.41% net margins and strong ROE of 128.38%. Technical indicators show a bearish trend with key support at $321, while analysts maintain a predominantly bullish outlook with a $370.59 consensus price target representing 12% upside potential.
The outlook balances near-term headwinds from weakening big-ticket demand and rising mortgage rates against long-term strengths in Pro segment growth and housing market tailwinds. Investment opportunities include the stock's discount to analyst targets and resilient business model, while risks include margin pressure from investments, competitive threats, and sensitivity to housing market cycles.
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
